NKARTA INC (NKTX) Stock Price, Quote, News and Overview
NASDAQ:NKTX - Nasdaq - US65487U1088 - Common Stock - Currency: USD
NKTX Quote, Performance and Key Statistics
NKARTA INC
NASDAQ:NKTX (1/31/2025, 8:00:01 PM)
After market: 2.34 0 (0%)2.34
-0.02 (-0.85%)
The current stock price of NKTX is 2.34 USD. In the past month the price decreased by -6.02%. In the past year, price decreased by -75.78%.
NKTX Latest News, Press Releases and Analysis
Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2
Ntrust-2 open to enroll patients with systemic sclerosis, myositis and ANCA-associated vasculitis across three parallel cohorts Investigator-Sponsored...
Nkarta to Participate in an Upcoming Investor Conference
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural...
Nkarta to Participate in an Upcoming Investor Conference
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural...
Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights
Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights
First patient dosed in each of Ntrust-1 and investigator-sponsored clinical trial (IST) of NKX019; enrollment ongoing in both studiesEnrollment in Ntrust-2...
NKTX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.11 | 324.98B | ||
| AMGN | AMGEN INC | 14.85 | 153.42B | ||
| GILD | GILEAD SCIENCES INC | 21.94 | 121.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 905.25 | 118.90B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.81 | 73.95B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.17B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.99B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.67B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.98B | ||
| NTRA | NATERA INC | N/A | 23.36B | ||
| BIIB | BIOGEN INC | 8.81 | 20.97B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 15.86B |
Related stock screener links
About NKTX
Company Profile
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 159 full-time employees. The company went IPO on 2020-07-10. The company is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. Both product candidates enable an on-demand, off-the-shelf approach involving scaled manufacturing to broaden patient access. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies. Its NKX019 oncology program is based on the potential to treat a variety of B-cell malignancies by targeting the CD19 antigen that is reliably expressed on these types of cancerous cells. Its NKX101 program is designed to enhance the power of innate NK cell biology to detect and kill cancerous cells.
Company Info
NKARTA INC
1150 Veterans Boulevard
South San Francisco CALIFORNIA 94080 US
CEO: Paul J. Hastings
Employees: 150
Company Website: https://www.nkartatx.com/
Investor Relations: https://ir.nkartatx.com/
Phone: 19254071049
NKTX FAQ
What is the stock price of NKTX?
The current stock price of NKTX is 2.34 USD.
What is the symbol for NKARTA INC stock?
The exchange symbol of NKARTA INC is NKTX and it is listed on the Nasdaq exchange.
On which exchange is NKTX stock listed?
NKTX stock is listed on the Nasdaq exchange.
Is NKTX a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for NKTX, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of NKTX.
Does NKTX stock pay dividends?
NKTX does not pay a dividend.
What is the Price/Earnings (PE) ratio of NKTX?
NKTX does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.88).
What is the Short Interest ratio of NKTX stock?
The outstanding short interest for NKTX is 15.21% of its float.
NKTX Technical Analysis
NKTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NKTX. NKTX has a great financial health rating, but its profitability evaluates not so good.
NKTX Financial Highlights
Over the last trailing twelve months NKTX reported a non-GAAP Earnings per Share(EPS) of -1.88. The EPS decreased by 22.31% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.79% | ||
| ROE | -25.67% | ||
| Debt/Equity | 0 |
NKTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to NKTX. The Buy consensus is the average rating of analysts ratings from 15 analysts.